← feed

Is NCT01231594 results overdue?

Yes — results are overdue. Primary completion was 2018-04-09; the FDAAA-801 reporting deadline (2019-04-09) passed 2676 days ago and no results are posted on ClinicalTrials.gov.

A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors

NCT IDNCT01231594 ↗
SponsorNovartis Pharmaceuticals (INDUSTRY)
Public issuerNOVARTIS AG — NVS (CIK 0001114448) best-effort name match, 95% conf — verify on EDGAR ↗
PhasePHASE1
StatusCOMPLETED
Primary completion2018-04-09 (ACTUAL)
Reporting deadline2019-04-09 (completion + 365d)
Days overdue2676
Results postedNo — check results tab ↗
FDA-regulateddrug: yes, device: no
ProvenanceFlagged overdue on 2026-06-21 · SHA-256 3d087907377f6947… (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT01231594. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.

⚠ Public-record facts from ClinicalTrials.gov — not a finding of violation, fraud, or non-compliance, and not legal or investment advice. Full disclaimer →